SK Biopharm expands global ties: what it means for SK Biopharm stock

Published on 10/14/2026 at 02:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SK Biopharm stock gets a pipeline reference from a USD 315.00 million deal. Revenue reached KRW 247.0 billion in Q2 2026.

Pipeline expansion and operating growth

SK Biopharm hosted a United States conference with 170 participants on October 10, 2026.
The company reported KRW 247.0 billion of revenue and KRW 97.1 billion of operating profit in the second quarter of 2026.
Two licensing deals announced in August and September 2026 carried potential values of USD 795.00 million and KRW 430.8 billion.

SK Biopharm, KR7326030004, Illustration mit AI erstellt.

SK Biopharm is widening its global research network after a New Jersey conference drew 170 participants on October 10, 2026. As DBR reported on October 12, 2026, the company used its cenobamate development and commercialization experience to discuss research, clinical approval and United States market access. The event gives SK Biopharm stock a measurable pipeline angle rather than a single-product story.

What does the conference change?

The conference linked the epilepsy drug cenobamate with the companys next stage of external collaboration. SK Biopharm and its United States subsidiary SK Life Science shared development experience with academic and industry participants, while the program covered three areas: research and development, clinical and regulatory work, and commercialization.

The commercial backdrop is already visible in the latest quarterly figures. ATS View reported revenue of KRW 247.0 billion and operating profit of KRW 97.1 billion for the second quarter of 2026. Revenue increased 40.3 percent year over year, and the operating margin reached 39.2 percent, giving the licensing strategy a stronger financial base.

Three dated pipeline milestones

The expansion accelerated through two licensing transactions. According to Pulse on September 23, 2026, the August 26, 2026 opakalim agreement with Biohaven carried potential payments of up to USD 795.00 million.

The second milestone came on September 17, 2026, when SK Biopharm signed a global licensing agreement for the Parkinsons candidate 1ST-104. Pulse put the potential value at KRW 430.8 billion, including a KRW 2.5 billion upfront payment and a separate KRW 3.0 billion equity investment. A separate News1 report described the same Parkinsons transaction as worth up to USD 315.00 million.

Listing and pipeline context

SK Biopharmaceuticals trades on the Korea Exchange KOSPI market under ticker 326030 and ISIN KR7326030004, according to Global Banking and Finance. The companys central nervous system focus now spans epilepsy, Parkinsons disease and additional external candidates.

The further course of trading is shown through the benchmark context of the South Korean equity market.